CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
J Westin, LH Sehn - Blood, The Journal of the American Society …, 2022 - ashpublications.org
The standard of care treatment strategy for patients with relapsed or refractory large B-cell
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …
[HTML][HTML] Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American …
MA Perales, LD Anderson Jr, T Jain… - … and cellular therapy, 2022 - Elsevier
ABSTRACT Since 2017, 3 CD19-directed chimeric antigen receptor (CAR) T cell therapies—
axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—have been …
axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel—have been …
Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/refractory large B-cell lymphoma
Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be
considered ineligible for curative-intent therapy including high-dose chemotherapy with …
considered ineligible for curative-intent therapy including high-dose chemotherapy with …
[HTML][HTML] The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: an economic evaluation …
MA Perales, J Kuruvilla, JT Snider, S Vadgama… - … and cellular therapy, 2022 - Elsevier
Axicabtagene ciloleucel (axi-cel) was found to have superior clinical outcomes compared to
standard of care (SOC; salvage chemoimmunotherapy, followed by high-dose therapy with …
standard of care (SOC; salvage chemoimmunotherapy, followed by high-dose therapy with …
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
J Wang, T Gu, Y Hu, H Huang - Experimental Hematology & Oncology, 2022 - Springer
Cellular immunotherapy, including the chimeric antigen receptor T (CAR-T) cell therapy and
CAR-natural killer (CAR-NK) cell therapy, has undergone extensive clinical investigation …
CAR-natural killer (CAR-NK) cell therapy, has undergone extensive clinical investigation …
CAR T-based therapies in lymphoma: a review of current practice and perspectives
S Sheikh, D Migliorini, N Lang - Biomedicines, 2022 - mdpi.com
While more than half of non-Hodgkin lymphomas (NHL) can be cured with modern frontline
chemoimmunotherapy regimens, outcomes of relapsed and/or refractory (r/r) disease in …
chemoimmunotherapy regimens, outcomes of relapsed and/or refractory (r/r) disease in …
Chimeric antigen receptor T cell therapy versus hematopoietic stem cell transplantation: an evolving perspective
SR Goldsmith, A Ghobadi, JF Dipersio, B Hill… - … and cellular therapy, 2022 - Elsevier
Cellular therapy modalities, including autologous (auto-) hematopoietic cell transplantation
(HCT), allogeneic (allo-) HCT, and now chimeric antigen receptor (CAR) T cell therapy, have …
(HCT), allogeneic (allo-) HCT, and now chimeric antigen receptor (CAR) T cell therapy, have …
Emerging role of autologous CD19 CAR T-cell therapies in the second-line setting for large B-cell lymphoma: a game changer?
Chimeric antigen receptor T-cell (CAR T) therapy has been proven effective in the third-line
(and beyond) setting in patients with large B-cell lymphoma (LBCL). Until recently, high …
(and beyond) setting in patients with large B-cell lymphoma (LBCL). Until recently, high …
Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial
ASL Loftager, A Danø, O Eklund… - Journal of Medical …, 2023 - Taylor & Francis
Aim Our study aimed to evaluate the cost-effectiveness of the chimeric antigen receptor
(CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel), compared to standard of care (SOC) …
(CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel), compared to standard of care (SOC) …
Understanding the differences in outcome between CART studies as second-line treatment in aggressive lymphoma
R Dada - Journal of Oncology Pharmacy Practice, 2023 - journals.sagepub.com
Patients with refractory/early relapsed aggressive lymphomas belong to the most difficult-to-
treat patients with hematological neoplasia. The prognosis of such patients is poor and …
treat patients with hematological neoplasia. The prognosis of such patients is poor and …